Durvalumab add-on therapy for previously untreated locally advanced cervical cancer

Durvalumab is in clinical development as an add-on treatment of female adults with previously untreated, locally advanced cervical cancer. Durvalumab will be added to the current treatment of concurrent chemotherapy and radiation therapy (cCRT). Cervical cancer arises when abnormal cells lining the cervix begin to grow uncontrollably and create tumours. Cervical cancer may not present symptoms, however the most common symptoms seen are unusual vaginal bleeding, pain during sex, vaginal discharge and pain in the pelvis. Increasing age and Human Papilloma Virus (HPV) infection are risk factors for the development of cervical cancer. Locally advanced cervical cancer means that the tumour is within the cervix (more than 4cm) or it has grown into the tissues around the cervix, but has not spread to other organs. cCRT is the only treatment currently recommended for previously untreated cervical cancer patients.